THE US Food and Drug Administration has granted accelerated approval for Keytruda (pembrolizumab) for the treatment of adult and paediatric patients with refractory classical Hodgkin lymphoma, or those who have relapsed after three or more prior lines of therapy.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Mar 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Mar 17